Charles River Laboratories Earnings In Retrospect: Down 0.6% in the Last 12 Days (CRL)
Comtex SmarTrend(R) - Mon May 12, 8:45AM CDT
A week ago on April 30th, 2014 Charles River Laboratories (NYSE:CRL) reported earnings and analysts, on average, expected earnings of $0.74 on sales of $302.2 million. Charles River Laboratories actually reported earnings of $0.82 per share on sales of $299.4 million, beating EPS estimates by $0.08 and missing revenue estimates by $2.8 million. Shares of Charles River Laboratories have slipped from $53.72 to $53.39, representing a loss of 0.6%, since the company reported earnings 12 days ago.
Earnings Results, Esteemed Recognitions, and Conference Call Schedules - Analyst Notes on Covance, Alere, LabCorp, Charles River and WuXi PharmaTech
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covance Inc. (NYSE: CVD), Alere Inc. (NYSE: ALR), Laboratory Corp. of America Holdings (NYSE: LH), Charles River Laboratories International, Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2179-100free.
Charles River Laboratories to Present at Baird's Growth Stock Conference
Business Wire - Mon May 05, 4:00PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at Baird's 2014 Growth Stock Conference in Chicago, Illinois on Wednesday, May 7th, at 10:20 a.m. CDT (11:20 a.m. EDT). Management will present an overview of Charles River's strategic focus and business developments.
Shares of CRL Down 11.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon May 05, 9:21AM CDT
SmarTrend identified a Downtrend for Charles River Laboratories (NYSE:CRL) on April 7th, 2014 at $56.82. In approximately 4 weeks, Charles River Laboratories has returned 11.85% as of today's recent price of $50.08.
Charles River Laboratories (CRL) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:50AM CDT
Charles River Laboratories (CRL) is now in Oversold Territory
Life Sciences BPO Market Report with Forecasts to 2019: Contract Research Organizations & Contract Manufacturing Organizations
M2 - Fri May 02, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zvdqxl/life_sciences_bpo) has announced the addition of the "Life Sciences BPO Market Report with Forecasts to 2019: Contract Research Organizations & Contract Manufacturing Organizations" report to their offering. The major players of this market are CatalentPharma Solutions, PRA International, Covance, Quintiles, Parexel, DSM, Charles River Laboratories, Piramal Healthcare and BoehringerIngelheim. Economic burden, increased financial crisis and technological advances has compelled all pharmaceutical, biotechnology and life science companies to outsource their R&D activities and manufacturing processes in order to achieve their cost benefits and save time.In recent years, large number of life science companies has modified their traditional drug manufacturing operations with more focus now on their core R&D activities and manufacturing processes via outsourcing. Global Life Sciences BPO market includes Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs) and others that compriseContract Sales Organization (CSO). The contract manufacturing organizations market is expected to see the highest growth rate during the forecast period and also accounted for the largest market share in the year 2012. This market holds immense growth owing to the rise in demand for generic drugs, increase in R&D investment by life sciences companies. In addition, a rise in the number of block buster drugs going off-patent and increased adoption of novel technologies are further boosting the growth of this market. The CMO market comprises contract API (Active Pharmaceutical Ingredients) manufacturing, contract FDF (Finished Dosage Formulations) manufacturing and packaging.Among these, contract FDF manufacturing segment is expected to have a healthy growth rate during the forecast period. The CRO market is also expected to display a healthy growth rate after CMO market. The CRO market comprises of various segments such as drug discovery, pre-clinical studies, clinical trial phases, medical writing, clinical data management, pharmacovigilance, regulatory services, site management, protocol development, monitoring and bio-statistics. Among these, clinical data management segment is expected to have a strong growth rate in coming years. This growth has been attributed to its high data complexities, high cost involvement and requirement of skilled & trained professionals. Scope Contract Research Organizations - Drug Discovery - Pre-Clinical - Clinical Trials - Medical Writing - Pharmacovigilance - Risk-Based Monitoring - Clinical Data Management - Biostatistics Contract Manufacturing Organizations Companies Mentioned - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/zv...iences_bpo
Charles River Beats on Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 2:34PM CDT
Charles River Laboratories (CRL) reported first quarter 2014 earnings (excluding special items) of 82 cents per share, easily beating the Zacks Consensus Estimate of 74 cents and up from 69 cents in the year-ago quarter.
Charles River Laboratories Announces First-Quarter 2014 Results from Continuing Operations
Business Wire - Wed Apr 30, 3:31PM CDT
--- First-Quarter GAAP Earnings per Share of $0.67 and Non-GAAP Earnings per Share of $0.82 -
Express Scripts Misses Earnings, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 10:50AM CDT
Express Scripts Holding Company (ESRX) posted first quarter 2014 earnings per share (excluding special items) of 99 cents, flat with the year-ago quarter. However, the result fell short of the Zacks Consensus Estimate of $1.01
Is Charles River Laboratories (CRL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:49AM CDT
Charles River Labs is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
IPC The Hospitalist (IPCM) in Focus: Stock Slumps 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 7:43AM CDT
IPC The Hospitalist falls 12.2% last trading session, continuing the downtrend
Research and Markets: Global In-vitro Toxicity Testing Market 2014-2018 with Accelrys, Bio-Rad Laboratories, Charles River Laboratories International & Covance Dominating
Business Wire - Wed Apr 23, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t58qhp/global_invitro) has announced the addition of the "Global In-vitro Toxicity Testing Market 2014-2018" report to their offering.
Global In-vitro Toxicity Testing Market 2014-2018 with Accelrys, Bio-Rad Laboratories, Charles River Laboratories International & Covance Dominating
M2 - Wed Apr 23, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7txnm/global_invitro) has announced the addition of the "Global In-vitro Toxicity Testing Market 2014-2018" report to their offering. The analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. The Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Animal welfare organizations across the world are supporting in vitro toxicity testing. Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as cruelty-free food, cosmetics, and clothing as cruelty-free testing does not damage the environment or produce harmful waste. For instance, the Body Shop follows a no-animal-tests policy to sell its products. Thus, the increase in animal-free testing campaigns has opened up new avenues for the market. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The Global In Vitro Toxicity Testing market can be divided into four end-user segments: - Cosmetics and Personal Care Industry - Pharmaceuticals Industry - Food Industry - Chemicals Industry. Key Vendors - Accelrys Inc. - Bio-Rad Laboratories Inc. - Charles River Laboratories International Inc. - Covance Inc. Other Prominent Vendors - Entelos Inc. - Mattek Corp. - Molecular Toxicology Inc. - RTI Health Solutions - SBW Ltd. - Smithers Group Inc. - Xenobiotic Detection Systems Inc. - Xenometrix AG Key Market Drivers/Challenges/Trends - Increasing Opposition to Animal Testing. - Concerns about Accuracy and Reliability of the Test. - Increase in Animal-free Testing Campaigns. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Toxicology - Market Landscape - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/p7...al_invitro
Technical Coverage on Health Care Equities -- Research on MEDNAX, Covance, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Apr 22, 11:55AM CDT
On Monday, April 21, 2014, the NASDAQ Composite ended at 4,121.55, up 0.64%, the Dow Jones Industrial Average advanced 0.25% to 16,449.25, and the S&P 500 closed at 1,871.89, up 0.38%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 666.48, up 1.20%, while the same has declined 3.26% in the last one month. Investor-Edge has initiated coverage on the following equities: MEDNAX Inc. (NYSE: MD), Covance Inc. (NYSE: CVD), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on MD, CVD, PRXL and CRL can be downloaded upon signing up at:
In Vitro Toxicity Testing to Grow at a 15.84% CAGR to 2018 Says a New Research Report at ReportsnReports.com
PRWeb - Mon Apr 14, 2:58AM CDT
Cosmetic as well as chemical companies are trying to market and sell their products by campaigning animal-free testing. Popular brands of cosmetics are implementing animal-free testing policies to market and sell their products. Vendors are targeting compassionate consumers by marketing their products as Cruelty-free food Cosmetics And clothing as cruelty-free testing does not damage the environment or produce harmful waste. Analysts forecast the Global In Vitro Toxicity Testing market will grow at a CAGR of 15.84 percent over the period 2013-2018. According to the report, the Global In Vitro Toxicity Testing market is driven by several factors, of which an increase in opposition to animal testing is one of the major drivers. Since animals are used as test subjects, toxicity testing is opposed by the majority of animal rights activists. This results in the increased adoption of in vitro toxicity testing and helps in the growth of the market. Covered in this Report The Global In Vitro Toxicity Testing market can be divided into four end-user segments: Cosmetics and Personal Care Industry, Pharmaceuticals Industry, Food Industry, and Chemicals Industry. The Global In Vitro Toxicity Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the market. In addition, the report discusses the major drivers that influence the growth of the Global In Vitro Toxicity Testing market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Accelrys Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Covance Inc. Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=280671. Other Prominent Vendors Entelos Inc. Mattek Corp. Molecular Toxicology Inc. RTI Health Solutions SBW Ltd. Smithers Group Inc. Xenobiotic Detection Systems Inc. Xenometrix AG Key Market Driver Increasing Opposition to Animal Testing. Key Market Challenge Concerns about Accuracy and Reliability of the Test. Key Market Trend Increase in Animal-free Testing Campaigns. Further, the report states that the accuracy and reliability of in vitro toxicity testing is one of the major challenges faced by the market vendors. In vitro toxicity testing requires proper laboratory setup as well as high-quality cell and tissue culture and good aseptic techniques. The report recognizes the following companies as the key players in Global In-vitro Toxicity Testing Market: Accelrys Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc. , Covance Inc. , Entelos Inc., MattekCorp., Molecular Toxicology Inc., RTI Health Solutions, SBW Ltd., Smithers Group Inc., Xenobiotic Detection SystemsInc., Xenometrix AG. Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Charles River Laboratories Schedules First-Quarter 2014 Earnings Release and Conference Call
Business Wire - Mon Apr 07, 3:15PM CDT
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2014 financial results on Wednesday, April 30th, after the market closes. A conference call has been scheduled to discuss this information on Thursday, May 1st, at 9:00 a.m. ET.
Pivotal Study Positive Results, Appointments, Proposed Public Offerings, Financial Results, and Product Launches - Analyst Notes on Amgen, Humana, Aetna, Perrigo, and Charles River
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen Inc. (NASDAQ: AMGN),
Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts
M2 - Tue Apr 01, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnnrlm/healthcare_bpo) has announced the addition of the "Global Healthcare BPO Market 2013-2018 - Payer, Provider & Pharmaceutical Trends & Forecasts" report to their offering. The global healthcare BPO market is dominated by the U.S. A very large percentage of the healthcare BPO requirement arises out of the U.S. Europe is quickly emerging as another important source segment in this market. The U.S. and India are the two largest destination geographies. Philippines and Eastern Europe are two of the fastest growing destination segments in this market. The payer market is segmented into claims processing, member services, HR services, and finance and accounts segments. Claims processing is an important service segment in the payer outsourcing market. It is further sub-divided into claims indexing, claims investigation, claims adjudication, claims repricing, claims settlement, litigation management, and information management. The provider market is segmented into medical billing, medical coding, medical transcription, and finance and account segments. The pharmaceutical outsourcing market is segmented into contract research organizations (CRO), contract manufacturing organizations (CMO), and business support services. Each service segment in the pharmaceutical outsourcing market is divided into further sub-segments. The CRO service segment is sub-divided into drug discovery, pre-clinical, clinical phases I, II, III and IV, clinical data management and biostatistics, medical writing, regulatory services, and non-clinical functions. The CMO service segment is sub-divided into API manufacturing, and formulation and packaging. The non-clinical service segment is sub-divided into supply chain management and logistics, sales and marketing, and non-clinical functions. The report also highlights the marketing KPO function in the sales and marketing outsourcing segment. Scope Healthcare BPO Market Payer - Claims Processing - HR Services - Finance & Accounts Provider - Medical Billing & Coding Pharmaceutical - Clinical Trial - Contract Manufacturing - Non-Clinical Services Key Topics Covered: - Introduction - Executive Summary - Market Overview - Healthcare Payer Outsourcing Market - Healthcare Provider Outsourcing Market - Pharmaceutical Outsourcing Market - Geographical Analysis - Competitive Landscape - Company Profiles - Accenture Plc - Accretive Health, Inc. - Anthelio Healthcare Solutions, Inc. - Boehringer Ingelheim Gmbh - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. - Cognizant Technology Solutions Corporation - Covance, Inc. - Gebbs Healthcare Solutions, Inc. - Genpact Limited - Ibm Corporation - Icon Plc - Igate Patni - Infosys Bpo Limited - Inventiv Health Inc - Lonza Group Ltd. - Medusind Solutions Inc - Mphasis Limited - Omega Healthcare Management Services Pvt Ltd - Parexel International Corporation - Patheon Inc - Pharmaceutical Product Development, Inc. - Piramal Enterprises Limited - Quintiles Transnational Holdings, Inc. - Tata Consultancy Services Ltd - Tech Mahindra - Teleradiology Solutions Pvt Ltd. - Wns (Holdings) Limited - Xerox Corporation Visit http://www.researchandmarkets.com/research/hn...thcare_bpo
Charles River Laboratories and Galapagos complete transaction
GlobeNewswire - Tue Apr 01, 12:36AM CDT
Galapagos NV (Euronext: GLPG) confirms the completion of the transaction announced on 13 March 2014 to sell the BioFocus and Argenta service division operations to Charles River Laboratories International, Inc. (NYSE: CRL) for a total consideration of up to EUR134 million.